" class="no-js "lang="en-US"> Oscar Health Announces Expansion with Vanderbilt University Medical Center To Provide In-Network Health Coverage for Residents Across the Nashville Region - Medtech Alert
Sunday, May 19, 2024

Oscar Health Announces Expansion with Vanderbilt University Medical Center To Provide In-Network Health Coverage for Residents Across the Nashville Region

Oscar Health, the first health insurance company built on a full stack technology platform, has announced that Vanderbilt University Medical Center (VUMC) is an in-network provider for Oscar Health in the Nashville, TN area. VUMC joins Oscar’s existing Southeast network as individuals are actively shopping for health insurance during this year’s Open Enrollment period. This network addition will help expand access for more individuals across the Nashville area and will bring VUMC providers and facilities in-network for individual and family health insurance plans from Oscar Health, beginning January 1, 2023.

“Having access to high-quality and affordable healthcare is critically important, and at Oscar we’ve made it our mission to ensure that individuals across the country have that option,” said Dennis Hillen, Senior Vice President at Oscar. “As we head into a new year, we are excited to work with Vanderbilt University Medical Center, an organization who shares that vision, and support more people in the Nashville region in their healthcare journeys.”

“We have spent the last decade expanding our health system so the patients we serve have convenient access to the broadest array of specialty services available in this region. Oscar’s progressive approach to care aligns well with our mission. We are excited to join with them to help serve their members,” said C. Wright Pinson, MBA, MD, Deputy Chief Executive Officer and Chief Health System Officer for VUMC.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more